Latest Global Partnerships News

Corporate Travel Management (ASX:CTD) has locked in a five-year global partnership with Amadeus IT Group, aiming to accelerate its digital transformation and operational efficiency across multiple regions.

Wellnex Life has agreed to sell its Pain Away brand to Mentholatum Australasia for up to A$21.3 million, aiming to wipe out debt and sharpen its strategic focus.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.

Arafura Rare Earths has committed to constructing the Nolans Rare Earths Project, Australia's first fully integrated ore-to-oxide operation, backed by binding offtake deals and sovereign financing. Construction is slated to start in September 2026, positioning Nolans as a strategic node in global rare earth supply chains.

RAS Technology Holdings has locked in new contracts and extensions expected to add at least $2 million in annualised revenue, reinforcing growth in wagering technology and international markets.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

ARN Media reported a 10% revenue decline in FY25 but accelerated digital growth and cost savings, while defending ongoing legal disputes with former talent.

Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.